GlassScriptPhysician profile
Allison H Conravey
NPI 1962693184
$14,832.07
in general payments reported to CMS, 2019-2025
26 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 78% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $152 · 2021: $122 · 2022: $1,333 · 2023: $3,694 · 2024: $6,606 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,540 · Consulting Fee: $3,600 · Travel and Lodging: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,539.61 |
| Consulting Fee | $3,600.00 |
| Travel and Lodging | $2,054.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $7,277.27 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Dixi Medical USA Corp | $1,813.68 | 2022-2023 | |
| Livanova USA, INC. | $1,483.58 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $1,472.75 | 2022-2025 | Epidiolex |
| Neurelis, INC. | $453.85 | 2023-2025 | Valtoco |
| Sk Life Science, INC. | $431.94 | 2022-2025 | Xcopri |
| Sunovion Pharmaceuticals INC. | $352.54 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $226.42 | 2019-2020 | |
| Greenwich Biosciences, INC. | $207.19 | 2019 | |
| Biocodex, INC. | $170.43 | 2023-2024 | Diacomit |
| Sarepta Therapeutics, INC. | $150.00 | 2023-2025 | Elevidys, Exondys 51 |
| Ptc Therapeutics, INC. | $137.89 | 2023-2025 | Emflaza |
| Biogen, INC. | $115.48 | 2023-2025 | Spinraza, Skyclarys |
| Eisai INC. | $73.14 | 2019 | |
| Zevra Therapeutics INC | $72.45 | 2025 | Olpruva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $57.59 | 2023-2024 | Eprontia, Zonisade |
| Genzyme Corporation | $52.69 | 2025 | |
| Aucta Pharmaceuticals, INC. | $49.20 | 2025 | Motpoly Xr |
| Acadia Pharmaceuticals INC | $46.92 | 2023-2025 | Daybue |
| Genentech USA, INC. | $44.17 | 2025 | Evrysdi |
| Zogenix INC. | $43.91 | 2021 | |
| Immedica Pharma US, INC. | $34.08 | 2023-2024 | |
| Upsher-Smith Laboratories LLC | $26.82 | 2025 | |
| Ns Pharma, INC. | $17.05 | 2024 | Viltepso |
| Biomarin Pharmaceutical INC. | $16.98 | 2023 | Brineura |
| Sumitomo Pharma America, INC. | $4.05 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Conravey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.